Fused heterocyclic derivatives and methods of use

US9066954B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Brian K. Albrecht · Cambridge, US
• David Bauer · Sudbury, US
• Steven Bellon · Wellesley, US
• Christiane M. Bode · Cambridge, US
• Shon Booker · Thousand Oaks, US
• Alessandro Boezio · Somerville, US
• Deborah Choquette · Medford, US
• Derin D'Amico · Newbury Park, US
• Jean-Christophe Harmange · Poissy, FR
• Satoko Hirai · Brookline, US
• Randall W. Hungate · Lansdale, US
• Tae-Seong Kim · Yongin-si, KR
• Richard T. Lewis · Missouri City, US
• Longbin Liu · Thousand Oaks, US
• Julia Lohman · Cambridge, US
• Mark H. Norman · Thousand Oaks, US
• Michele Potashman · Cambridge, US
• Aaron C. Siegmund · Ventura, US
• Stephanie Springer · Cambridge, US
• Markian Stec · Thousand Oaks, US
• Ning Xi · Newbury Park, US
• Kevin Yang · San Gabriel, US

Key dates

• Filing date: Jun 13, 2013
• Grant date: Jun 30, 2015
• Expiry date: Jun 13, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.